Transcatheter Closure of Congenital Defects ranscatheter Closure of Perimembranous entricular Septal Defects Using the New mplatzer Membranous VSD Occluder esults

@inproceedings{Bass2016TranscatheterCO,
  title={Transcatheter Closure of Congenital Defects ranscatheter Closure of Perimembranous entricular Septal Defects Using the New mplatzer Membranous VSD Occluder esults},
  author={John L. Bass and Zahid Amin and olfgang Radtke and John P. Cheatham and William E. Hellenbrand and A Balzer and Qi-ling Cao and Ziyad M. Hijazi},
  year={2016}
}
OBJECTIVES This phase I study attempted to report the initial safety and efficacy results of transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S. BACKGROUND The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but still carries a small but definite risk of morbidity and mortality. METHODS Between October 2003 and August 2004, a total… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Three patients ( 8.6% ) had serious adverse events of complete heart block , peri - hepatic bleeding , and rupture of tricuspid valve chordae tendineae .
Three patients ( 8.6% ) had serious adverse events of complete heart block , peri - hepatic bleeding , and rupture of tricuspid valve chordae tendineae .
All Topics